+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Gastric Ulcer Treatment Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 5997744
The gastric ulcer treatment market was valued at USD 2.12 Billion in 2024, driven by the rising incidence of gastric ulcers and related complications across the 8 major markets. It is expected to grow at a CAGR of 2.80% during the forecast period of 2025-2034, with the values likely to reach USD 2.79 Billion by 2034.

Gastric Ulcer Treatment Market Overview

Gastric ulcers, also known as stomach ulcers, are open sores that develop on the inner lining of the stomach. They occur when the stomach's protective mucus layer is damaged, allowing stomach acid to erode the underlying tissue. This can cause pain, bleeding, and other gastrointestinal symptoms. Gastric ulcers are often caused by infections with Helicobacter pylori bacteria or the prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs). Treatment typically involves the use of medications such as proton pump inhibitors (PPIs) and H2 receptor antagonists to reduce stomach acid, antibiotics to eradicate Helicobacter pylori infection, and lifestyle modifications to address contributing factors like diet and NSAID use. In some cases, treatment may also include antacids, protective agents, and surgical procedures for severe or complicated ulcers.

The gastric ulcer treatment market is expanding due to growing healthcare spending in developing and developed countries enhancing access to advanced ulcer treatments. Expanding healthcare infrastructure in emerging markets increases the availability and accessibility of gastric ulcer treatments. Also, unhealthy lifestyle habits, such as poor diet, smoking, and excessive alcohol consumption, contribute to the increasing prevalence of gastric ulcers, driving the need for treatments.

Gastric Ulcer Treatment Market Growth Drivers

Advancements in Medical Research Augmenting the Market Growth

Advancements in medical research are crucial for the development of new and more effective treatments for gastric ulcers. These innovations lead to better therapeutic options, improving patient outcomes and driving market growth. For Instance, in January 2023, Takeda announced favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura (cTTP). The trial also assessed the pharmacokinetics (PK) characteristics of TAK-755, along with long-term data on TAK-755 prophylaxis from a Phase 3b continuation study. This new medication, developed through advanced research and innovative drug design, promises to provide enhanced relief for patients with gastric ulcers, highlighting the impact of ongoing medical research on market growth.

Strategic Collaborations and Partnerships to Meet Rising Gastric Ulcer Treatment Market Demand

Strategic collaborations and partnerships between pharmaceutical companies are accelerating the development and commercialization of new gastric ulcer treatments. These alliances combine resources and expertise, leading to innovative solutions and faster market entry. For Instance, AstraZeneca plc and Daiichi Sankyo Company Limited in collaboration announced the launch of Nexium® Granules for Suspension, Sachet, in 10 mg and 20 mg doses (generic name: esomeprazole magnesium hydrate). It is a proton pump inhibitor indicated for gastric ulcers, duodenal ulcers, anastomotic ulcers, reflux esophagitis, and nonerosive reflux disease. This partnership aimed to leverage AstraZeneca’s expertise in gastrointestinal therapies and Daiichi Sankyo’s advanced drug development technologies. The collaboration is expected to expedite the availability of this new treatment, demonstrating how strategic partnerships drive innovation and growth in the gastric ulcer treatment market.

Gastric Ulcer Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

The widespread dependence on NSAIDs as a treatment for various indications is boosting the demand for gastric ulcer treatment, as this category of drugs is often associated with ulcer-related complications.

Rising Helicobacter pylori Infection

The high prevalence of Helicobacter pylori infection is one of the major causes of gastric ulcers, driving the demand for appropriate therapies.

Technological Advancements

Innovations in drug delivery systems and treatment methodologies enhance the efficacy and patient compliance of gastric ulcer treatments.

Regulatory Approvals

Favorable regulatory policies and faster approval processes for new gastric ulcer treatments are some of the major market trends, supporting market growth significantly.

Gastric Ulcer Treatment Market Segmentation

“Gastric Ulcer Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

  • Antacids
  • Anti-Histamines
  • Antibiotics
  • H2 Receptor Antagonist
  • Proton Pump Inhibitor (PPIs)

Market Breakup by Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

Market Breakup by Route of Administration

  • Oral
  • Parenteral

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Gastric Ulcer Treatment Market Share

Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth

By Drug Class, the market is segmented into antacids, anti-histamines, antibiotics, H2 receptor antagonists, and proton pump inhibitors (PPIs). Increasing disposable income in emerging markets allows for greater spending on healthcare and advanced treatments for gastric ulcers. Collaborations between pharmaceutical companies and research institutions are accelerating the development of new treatments and expanding market reach. Growing preference for non-invasive and minimally invasive treatments boosts the demand for advanced therapeutic options for gastric ulcers.

Gastric Ulcer Treatment Market Analysis by Region

Based on the region, the market report covers the United States, EU-4 and the United Kingdom (Germany, France, Italy, Spain, United Kingdom), Japan, and India. The United States is dominating the market share due to the high economic burden of managing chronic diseases, motivating the adoption of effective treatments like gastric ulcer treatment to improve patient outcomes and reduce healthcare costs.

EU-4 also holds a high gastric ulcer treatment market value driven by the improvements in healthcare infrastructure in emerging markets increasing the availability and adoption of gastric ulcer treatment. Additionally, Japan is expected to witness substantial market growth fueled by the growing patient pool and the increasing recognition of gastric ulcer treatment benefits. An aging population is more susceptible to chronic diseases, thereby increasing the demand for gastric ulcer treatment.

Leading Players in the Gastric Ulcer Treatment Market

The key features of the market report include patent analysis, clinical trials analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AstraZeneca PLC

It is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and respiratory therapy areas. In the field of gastric ulcer treatment, AstraZeneca is known for developing effective medications such as proton pump inhibitors (e.g., Nexium) that reduce stomach acid and promote ulcer healing. The company leverages its extensive research and development capabilities to continuously innovate and improve treatment options for gastric ulcers and other gastrointestinal conditions.

Takeda Pharmaceutical Company Limited

A global, research and development-driven biopharmaceutical company headquartered in Japan, Takeda focuses on developing innovative medicines in areas such as oncology, gastroenterology, neuroscience, and rare diseases. In the realm of gastric ulcer treatment, it offers effective therapies like proton pump inhibitors (e.g., Lansoprazole) that help reduce stomach acid and promote healing. The company is committed to improving patient outcomes through advanced research and a strong pipeline of therapeutic solutions.

Other key players in the market include Boehringer Ingelheim International GmbH, Nuvo Pharmaceuticals Inc. (Aralez Pharmaceuticals), Daiichi Sankyo Company, Limited, Novartis AG, and Pfizer Inc., among others.

Key Questions Answered in the Gastric Ulcer Treatment Market Report

  • What was the 8 MM gastric ulcer treatment market value in 2024?
  • What is the 8MM gastric ulcer treatment market forecast outlook for 2025-2034?
  • What are the regional markets covered in the report?
  • What is market segmentation based on the drug class?
  • What is market segmentation based on the distribution channel?
  • What is market segmentation based on the route of administration?
  • What are the major factors aiding the gastric ulcer treatment market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major market trends influencing the market?
  • What are the market's major drivers, opportunities, and restraints?
  • Which regional market is expected to lead the market share in the forecast period?
  • Which country is expected to experience expedited growth during the forecast period?
  • How does the rise in the geriatric population impact the market size?
  • How do the technological innovations in gastric ulcer treatment affect the market landscape?
  • Which application area is expected to have a high market value in the coming years?
  • Who are the key players involved in the gastric ulcer treatment market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Gastric Ulcer Treatment Market Overview - 8 Major Markets
3.1 Gastric Ulcer Treatment Market Historical Value (2018-2024)
3.2 Gastric Ulcer Treatment Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Gastric Ulcer Treatment Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Treatment Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Treatment Success Rate
7 Gastric Ulcer Treatment Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality, by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment seeking rate, by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Gastric Ulcer Treatment Market Landscape - 8 Major Markets
8.1 Gastric Ulcer Treatment: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Gastric Ulcer Treatment: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Gastric Ulcer Treatment Challenges and Unmet Needs
9.1 Treatment Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Treatment
11 Gastric Ulcer Treatment Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Gastric Ulcer Treatment Market Segmentation (218-2034) - 8 Major Markets
12.1 Gastric Ulcer Treatment Market (2018-2034) by Drug Class
12.1.1 Market Overview
12.1.2 Antacids
12.1.3 Anti-Histamines
12.1.4 Antibiotics
12.1.5 H2 Receptor Antagonist
12.1.6 Proton Pump Inhibitor (PPIs)
12.2 Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
12.2.1 Market Overview
12.2.2 Retail Pharmacy
12.2.3 Hospital Pharmacy
12.2.4 Online Pharmacy
12.3 Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
12.3.1 Market Overview
12.3.2 Oral
12.3.3 Parenteral
12.4 Gastric Ulcer Treatment Market (2018-2034) by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Gastric Ulcer Treatment Market (218-2034)
13.1 United States Gastric Ulcer Treatment Market Historical Value (2018-2024)
13.2 United States Gastric Ulcer Treatment Market Forecast Value (2025-2034)
13.3 United States Gastric Ulcer Treatment Market (2018-2034) by Drug Class
13.3.1 Market Overview
13.3.2 Antacids
13.3.3 Anti-histamines
13.3.4 Antibiotics
13.3.5 H2 Receptor Antagonist
13.3.6 Proton Pump Inhibitor (PPIs)
13.4 United States Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
13.4.1 Market Overview
13.4.2 Retail Pharmacy
13.4.3 Hospital Pharmacy
13.4.4 Online Pharmacy
13.5 United States Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
13.5.1 Market Overview
13.5.2 Oral
13.5.3 Parenteral
14 EU-4 and United Kingdom Gastric Ulcer Treatment Market (218-2034)
14.1 EU-4 and United Kingdom Gastric Ulcer Treatment Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Gastric Ulcer Treatment Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Gastric Ulcer Treatment Market (2018-2034) by Drug Class
14.3.1 Market Overview
14.3.2 Antacids
14.3.3 Anti-Histamines
14.3.4 Antibiotics
14.3.5 H2 Receptor Antagonist
14.3.6 Proton Pump Inhibitor (PPIs)
14.4 EU-4 and United Kingdom Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
14.4.1 Market Overview
14.4.2 Retail Pharmacy
14.4.3 Hospital Pharmacy
14.5 EU-4 and United Kingdom Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
14.5.1 Market Overview
14.5.2 Oral
14.5.3 Parenteral
15 Japan Gastric Ulcer Treatment Market
15.1 Japan Gastric Ulcer Treatment Market Historical Value (2018-2024)
15.2 Japan Gastric Ulcer Treatment Market Forecast Value (2025-2034)
15.3 Japan Gastric Ulcer Treatment Market (2018-2034) by Drug Class
15.3.1 Market Overview
15.3.2 Antacids
15.3.3 Anti-Histamines
15.3.4 Antibiotics
15.3.5 H2 Receptor Antagonist
15.3.6 Proton Pump Inhibitor (PPIs)
15.4 Japan Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
15.4.1 Market Overview
15.4.2 Retail Pharmacy
15.4.3 Hospital Pharmacy
15.4.4 Online Pharmacy
15.5 Japan Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
15.5.1 Market Overview
15.5.2 Oral
15.5.3 Parenteral
16 India Gastric Ulcer Treatment Market
16.1 India Gastric Ulcer Treatment Market (2018-2034) Historical Value (2018-2024)
16.2 India Gastric Ulcer Treatment Market (2018-2034) Forecast Value (2025-2034)
16.3 India Gastric Ulcer Treatment Market (2018-2034) by Drug Class
16.3.1 Market Overview
16.3.2 Antacids
16.3.3 Anti-Histamines
16.3.4 Antibiotics
16.3.5 H2 Receptor Antagonist
16.3.6 Proton Pump Inhibitor (PPIs)
16.4 India Gastric Ulcer Treatment Market (2018-2034) by Distribution Channel
16.4.1 Market Overview
16.4.2 Retail Pharmacy
16.4.3 Hospital Pharmacy
16.4.4 Online Pharmacy
16.5 India Gastric Ulcer Treatment Market (2018-2034) by Route of Administration
16.5.1 Market Overview
16.5.2 Oral
16.5.3 Parenteral
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 Japan PMDA
17.1.4 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Strategic Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Market Share by Top 5 Companies
21.2 AstraZeneca PLC
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Takeda Pharmaceutical Company Limited
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Boehringer Ingelheim International GmbH
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Nuvo Pharmaceuticals Inc. (Aralez Pharmaceuticals)
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Daiichi Sankyo Company, Limited
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Novartis AG
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Pfizer, Inc
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
22 Gastric Ulcer Treatment Treatment Drugs - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket

Companies Mentioned

  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

Table Information